The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
- Investigator
- Wai L Lau
- Status
- Accepting Candidates
- Ages
- 10 Years - 65 Years
- Sexes
- All